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Caged-Iron Chelators a Novel Approach towards
Protecting Skin Cells against UVA-Induced Necrotic
Cell Death
Anthie Yiakouvaki1,3, Jelena Savovic´1,3, Abdullah Al-Qenaei1, James Dowden2 and Charareh Pourzand1
Exposure of human skin cells to solar UVA radiation leads to an immediate dose-dependent increase of labile
iron that subsequently promotes oxidative damage and necrotic cell death. Strong iron chelators have been
shown to suppress cell damage and necrotic cell death by moderating the amount of labile iron pool (LIP), but
chronic use would cause severe side effects owing to systemic iron depletion. Prodrugs that become activated
in skin cells at physiologically relevant doses of UVA, such as ‘‘caged-iron chelators’’, may provide dose- and
context-dependent release. Herein, we describe prototypical iron chelator compounds derived from
salicylaldehyde isonicotinoyl hydrazone and pyridoxal isonicotinoyl hydrazone and demonstrate that the
intracellular LIP and subsequent necrotic cell death of human skin fibroblasts is significantly decreased upon
exposure to a combination of the prototypical compounds and physiologically relevant UVA doses. Iron
regulatory protein bandshift and calcein fluorescence assays reveal decreased intracellular LIP following
irradiation of caged-chelator-treated cells, but not in control samples where either UVA light, or caged-chelator
is absent. Furthermore, flow cytometry shows that these compounds have no significant toxicity in the skin
fibroblasts. This novel light-activated prodrug strategy may therefore be used to protect skin cells against the
deleterious effects of sunlight.
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INTRODUCTION
There is significant interest in understanding and controll-
ing the cellular mechanisms that cause skin damage upon
prolonged exposure to the UV component of sunlight. It is
now known that UVA radiation of skin cells leads to an
immediate release of labile iron (Pourzand et al., 1999) and
susceptibility to both oxidative membrane damage and
necrotic cell death owing to a loss of plasma membrane
integrity, presumably as a result of iron-catalyzed biological
oxidation (Reelfs et al., 2004; Zhong et al., 2004). Damage
owing to further exposure to UVA is likely to be further
exacerbated as a result (Zhong et al., 2004).
Normally, the cellular labile iron pool (LIP) (see, Kakhlon
and Cabantchik, 2002) is tightly regulated (Breuer et al.,
1996; Epsztejn et al., 1997; Cairo and Pietrangelo, 2000;
Petrat et al., 2001) by cytosolic iron regulatory proteins 1 and
2 (IRPs) (Beinert and Kennedy, 1993; Klausner et al., 1993;
Kuhn, 1994; Guo et al., 1995; Hentze and Kuhn, 1996), but
pathological conditions that severely alter iron homeostasis
(Cairo et al., 1995, 1996; Martins et al., 1995; Pantopoulos
and Hentze, 1995; Pourzand et al., 1999) lead to enhanced
oxidative cell injury.
Iron chelation offers a simple method of rectifying
unbalanced iron levels. Bisset et al. (1991) emphasized the
importance of topical iron chelators to protect skin cells
against the UV-induced increase in skin iron. Strong iron
chelators such as desferrioxamine mesylate (DFO) suppress
both cell damage (Zhong et al., 2004) and iron release
(Pourzand et al., 1999; Kvam et al., 2000; Reelfs et al., 2004;
Zhong et al., 2004) induced by UVA. Unfortunately, pro-
longed dosing with exposure to strong iron chelators leads to
side effects as a result of the removal of essential iron from
various sites including iron-containing enzymes (Porter and
Huens, 1989; Singh et al., 1995; Hileti et al., 1995; Rakba
et al., 2000; Simonart et al., 2000). To minimize these sides
effects, a series of photoprotective iron chelation strate-
gies have been proposed in oxidative conditions (Galey
et al., 2000; Se´ite´ et al., 2004). Alternatively, design of mild
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chelators (Kitazawa et al., 2005) have been reported to
reduce considerably the observed toxic side effects by strong
chelators such as induction of hypoxia-inducing factor-1, as
demonstrated in a study by Creighton-Gutteridge and Tyrrell
(2002).
We envisaged that caged iron chelators, rendered inactive
by a photolabile protecting group that is later released upon
exposure to UV irradiation, would potentially reduce side
effects arising from chronic exposure to iron chelators. Under
normal conditions, such compounds would have low affinity
for iron and become dispersed within skin cells without
causing iron starvation. However, photolysis (UVA radiation)
would furnish the highly potent uncaged chelator capable of
effective chelation and removal of the UVA-induced labile
iron. Simple prototypical compounds derived from strong
iron chelators salicylaldehyde isonicotinoyl hydrazone (SIH)
and pyridoxal isonicotinoyl hydrazone (PIH), elaborated with
the 1-(2-nitrophenyl)ethyl (2-NPE) caging group (Figure 1),
were thus synthesized. Both SIH and PIH are Fe(III)-specific
tridentate ligands that chelate iron as effectively as DFO
and are powerful inhibitors of iron-dependent production
of hydroxyl radicals from hydrogen peroxide, mitochondrial
lipid peroxidation, and other oxidative injuries as demon-
strated in a series of cellular and animal studies (Hershko
et al., 1981; Richardson and Ponka, 1998; Hermes-Lima
et al., 1999; Horackova et al., 2000; Santos et al., 2001;
Chaston and Richardson, 2003; Buss et al., 2003a; Sˇimunek
et al., 2005). Additionally, hydrophilic iron chelators, such
as DFO, are poorly cell permeant, whereas lipophilic PIH
and SIH efficiently enter cells and tissues (Ponka et al.,
1979, 1994; Huang and Ponka, 1983; Epsztejn et al., 1997).
The chelator SIH is sufficiently lipophilic to readily cross the
cell membrane and even transport iron (i.e. redox-inactive
iron) to the extracellular media.
To test this concept, caged iron chelators were examined
for (i) ‘‘uncaging’’ by broad-spectrum UVA radiation at a
physiological relevant dose; (ii) iron chelation by caged and
uncaged products in vitro; (iii) modulation of the intracellular
labile iron concentration before, and following UVA-irradi-
ation of a human skin fibroblast cell line, FEK4; and (iv)
protection of skin cells from oxidative damage following
radiation treatment. Our results demonstrate that unlike the
parent compounds, the caged iron chelators do not diminish
the normal LIP in cells, until exposure to a physiologically
relevant UVA dose when they subsequently provide promis-
ing levels of protection for skin fibroblast cells against UVA-
mediated necrotic cell death.
RESULTS
Chemistry: synthesis of caged compounds and analogues
The phenol group is involved in co-ordination to iron in the
chelate and was the first choice for blocking with the caging
group. Salicylaldehyde or pyridoxal was alkylated under
basic conditions with 1-(1-bromo-ethyl)-2-nitro-benzene (or
benzyl bromide). Condensation of the appropriate aldehydes
with isonicotinic acid hydrazide provided the respective
Schiff bases in good yield. Spectrophotometric titration
(Avramovici-Grisaru et al., 1983) confirmed that all com-
pounds that displayed a blocked or deleted phenol did not
bind to iron (data not shown). The efficiency of in vitro
decaging under physiologically relevant doses of UVA-
irradiation was examined for 2-NPE-SIH using high perfor-
mance liquid chromatography (Figure 2). This confirmed that
decaging was efficient at these wavelengths, providing clean
conversion to the parent compound.
Cell biology: determination of basal and UVA-induced LIP
levels in the primary fibroblast cell line FEK4
The IRP-1/IRE RNA bandshift assay (see, Henderson et al.,
1996) was used to estimate the intracellular basal level of LIP
OO
O
N
OH
Br
a, b
OH
O2N
O2N
O2N
O2N
1 2NPE-PIH;
Scheme
N
N
N
N
N
R
R
2 2NPE-SIH;
3 BIH; R = H
4 SIH; R = OH
5 BnSIH; R = OCH2Ph
O
O
OO
HO
H
N
N
N
N
N
NH
H
HO
+
=
Figure 1. Structures of caged iron chelators and control compounds.
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Figure 2. HPLC comparison of SIH and 2-NPE-SIH. (a) 2-NPE-SIH (0.1 mm in
CH3CN/aq 1:1); (b) same sample after irradiation with 250kJ/m
2 UVA; and
(c) irradiated sample with SIH co-injection.
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in cells treated with either DFO (i.e. positive control) or a
series of freshly synthesized compounds 1–5 (Figure 1),
namely iron chelators SIH and PIH and their respective caged
analogues 2-NPE-SIH and 2-NPE-PIH and BIH (Benzal-
dehyde isonicotinoyl hydrazone, see, Buss et al., 2003b)
and BnSIH ((isonicotinic acid (2-benzyloxy-benzylidene)-
hydrazide)) as non-chelating analogues. Flow cytometry
revealed that treatment of cells with any of the compounds
for 18 hours at 371C was not toxic up to a final concentration
of 250mM (data not shown). The minimum effective
concentration of SIH and PIH was found to be 20 mM, as this
was sufficient to activate IRP-1 even at short incubation
period (i.e. 30 minutes, data not shown). Figure 3 represents
an example of IRP1-IRE bandshift assay carried out with cells
treated with 100 mM of the compounds for 18 hours. The
treatment of cells with SIH, PIH, and DFO strongly activated
the IRP-1-binding activity in response to iron chelation.
Modifying the phenolic iron-binding site of SIH in BnSIH, or
depleting its phenol moiety in BIH, completely abolished the
IRP-1 activation to untreated control levels. Most importantly,
cells treated with SIH and PIH elaborated with the 2-NPE
caging group (i.e. caged compounds) showed unchanged
basal IRP-1 activity, confirming that 2-NPE caging groups are
capable of efficiently masking the iron-binding sites of both
PIH and SIH chelators.
The calcein (CA) assay was then used to investigate these
compounds pre- and post-UVA-irradiation with respect to
modulating the intracellular levels of LIP. Cells were treated
with individual compounds (20–250 mM) for a total of between
15 minutes and 18 hours, and then irradiated with a UVA
dose of 250 kJ/m2 equivalent to 70 minutes sunlight exposure
on a summer day around noon at northern latitude of 30–351
(Frederick and Lubin, 1988). Table 1 provides an example of
the CA assays carried out immediately after UVA-irradiation
of cells pretreated for 18 hours with compounds at a final
concentration of 100 mM. These data, in agreement with that
of IRP-1/IRE bandshift assay (see Figure 3), illustrate that sham
irradiation of analogues lacking an effective iron-binding site,
that is, BIH and BnSIH and the caged compounds 2-NPE-SIH
or 2-NPE-PIH, failed to modulate the basal level concen-
trations of LIP in FEK4 fibroblasts. UVA-induced rises in
intracellular LIP was only observed for BIH- and BnSIH-
treated cells, consistent with the notion that these compounds
are not capable of chelating labile iron. As true time controls,
both SIH and PIH were added to irradiation medium for the
duration of radiation treatment. This was thought to mimic
the time necessary for the caged compounds to be uncaged
upon radiation treatment so that they acquire the ability to
chelate iron. Our data demonstrated that unlike caged
compounds, the addition of PIH or SIH either for duration
of irradiation or 18 hours (not shown) led to complete
depletion of both basal and UVA-induced LIP (see Tables 1
and 2).
UVA-irradiation of caged-SIH- or caged-PIH-treated cells
revealed a significant reduction in the UVA-induced increase
in LIP (i.e. to control levels) when compared to the corres-
ponding UVA-irradiated samples. The latter result strongly
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Figure 3. Effect of SIH, PIH, and its derivatives on modulation of IRP1-
binding activity in FEK4 fibroblasts. Cells were first treated (or not, for
Control) for 18 hours with 100 mM of compounds PIH, SIH, BIH, BnSIH,
3-NPE-SIH, 2-NPE-PIH, and DFO. (a) Next, the intracellular level of LIP
was estimated by IRP-1-IRE bandshift assay. (b) The IRP/IRE signals were
then quantified and their relative intensities normalised against that of
untreated ‘‘Control’’ cells and then expressed as a fold increase in IRP-1
binding activity above control value.
Table 1. Modulation of LIP levels following irradiation
of fibroblasts with UVA
FEK4 condition [LIP]lM
Control 0.9770.45
+UVA 2.4670.67*
BIH 0.9770.11
BIH+UVA 1.9270.09*
BnSIH 1.0170.19
BnSIH+UVA 2.0570.31*
2-NPE-SIH 0.9870.12
2-NPE-SIH+UVA 0.9570.23
2-NPE-PIH 0.9470.26
2-NPE-PIH+UVA 1.0670.33
SIH 0
SIH+UVA 0
PIH 0
PIH+UVA 0
DFO 0
DFO+UVA 0
Note: Cells were first treated with compounds (100 mM) for 18 h (except
PIH and SIH that were added to the irradiation medium for the duration of
irradiation, that is, 15 min) and then irradiated (or sham irradiated) with a
UVA dose of 250 kJ/m2. Measurements were performed in both sham-
irradiated and UVA-irradiated samples (i.e. +UVA) immediately after
radiation treatment. Kd of CA-Fe for FEK4 was 12.7.The concentrations of
LIP are expressed as means7SD, n=5–7.
*Significantly different from sham-irradiated control, Po0.05.
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suggests that UVA-irradiation is responsible for photolytic
release of either SIH or PIH, which subsequently remove
excess labile iron by chelation and transport. Intracellular LIP
levels for caged-compound-treated cells were re-examined
up to 18 hours following radiation treatment. Sham-irradiated
cells treated with caged compounds did not show modulation
of basal LIP levels, whereas the equivalent UVA-irradiated
population treated with caged compounds apparently conti-
nued to show a decrease in the intracellular LIP level because
from 1 hour post-irradiation time onwards no intracellular
labile iron was detectable (see the example of 2-NPE-PIH in
Table 2). A similar time-dependent increase in the binding
activity of IRP-1 activity was also observed for the equivalent
IRP-1/IRE RNA bandshift assays (data not shown).
Finally, 2-NPE-PIH-treated cells were challenged with
hydrogen peroxide, which is also known to cause oxidative
damage via an increase in labile iron immediately following
oxidizing insult in FEK4 cells (unpublished data, this labora-
tory). That an increase in labile iron occurred to the same
extent in either untreated control cells, or those subject to
2-NPE-PIH is consistent with the notion that UVA-irradiation
leads to ablation of the caging group, whereas treatment with
hydrogen peroxide does not, so that iron removal observed
upon photolysis is likely owing to chelation and transport by
the PIH photoproduct (see Table 3).
Determination of the level of UVA-mediated cell death
in fibroblasts following treatment with the synthesized
compounds
Recent studies in our laboratory have provided a strong link
between the level of UVA-induced labile iron release and the
extent of necrotic cell death in human skin fibroblasts (Zhong
et al., 2004). Furthermore, it was demonstrated that pretreat-
ment of fibroblasts with strong iron chelator DFO signi-
ficantly decreases the level of UVA-induced necrotic cell
death. Based on these findings, we hypothesized that strong
iron chelators such as SIH and PIH that also abolish the
intracellular LIP should provide protection against UVA-
induced necrotic cell death. On the other hand, control
compounds BIH and BnSIH that lack iron-binding site should
have no protective effect. Additionally, the caged-chelators
that are only competent after UVA-irradiation (see Tables 1
and 2, and data not shown) should protect against UVA-
induced cell death. For this purpose, FEK4 fibroblasts were
treated for 18 hours with a range of concentrations of SIH,
PIH, BnSIH, BIH, 2-NPE-SIH, and 2-NPE-PIH (i.e. 20–250 mM)
and then the percentage of apoptotic and necrotic cells in
UVA-irradiated fibroblasts were scored by flow cytometry
using the dual propidium iodide (PI) uptake/Annexin V-FITC
binding assay (see Figures 4 and 5) and confirmed by the
Apoglow assay that monitors the immediate depletion of
intracellular ATP, a recognized hallmark of necrotic cell
death (data not shown) (see, Egushi et al., 1997; Leist et al.,
1997; Ha and Snyder, 1999; Zhong et al., 2004). In agree-
ment with our previous studies (Pourzand and Tyrrell, 1999;
Zhong et al., 2004), UVA induced a dose-dependent increase
in necrotic cell death (Figure 4) and the fibroblast cells
remained fairly resistant to UVA-induced apoptosis (data not
shown). Both SIH and PIH were effective in decreasing the
UVA-induced necrotic cell death over the concentration
range of 20–250 mM, although optimum protection was obser-
ved from 100mM onwards (e.g. Figure 4a and b). In addition,
Table 2. Time course of intracellular LIP levels in FEK4 cells following irradiation of fibroblasts with UVA
Time post-UVA (h)
LIP (lM)
control
LIP (lM)
UVA
LIP (lM)
2-NPE-PIH
LIP (lM)
NPE-PIH+UVA LIP (lM) PIH
LIP (lM)
PIH+UVA
0 0.9770.45 2.4670.67* 0.9470.26 1.067 0.33 0 0
1 0.9970.18 1.7270.19* 0.9170.20 0 0 0
2 0.9270.14 1.4770.28* 0.8870.35 0 0 0
4 0.9570.23 1.2270.27 0.9370.31 0 0 0
6 0.9670.33 0.9270.16 0.9070.21 0 0 0
18 0.9470.37 0.8970.29 0.9570.38 0 0 0
Note: Cells were first treated with compounds for 18 h (except PIH that was added to the irradiation medium for the duration of irradiation time, that is,
15 min) and then irradiated (or sham-irradiated) with a UVA dose of 250 kJ/m2. Measurements were performed in both sham-irradiated and UVA-irradiated
samples (i.e. +UV) at indicated times after radiation treatment. Kd of CA-Fe for FEK4 was 12.7. The concentrations of LIP are expressed as means7SD,
n=5–7.
*Significantly different from the corresponding sham-irradiated control, Po0.05.
Table 3. Modulation of LIP levels following treatment
of fibroblasts with H2O2
FEK4 condition [LIP]lM
Control 1.1770.19
100 mM H2O2 1.9070.08*
2-NPE-PIH 0.8270.09
2-NPE-PIH+100 mM H2O2 2.2670.60*
PIH 0
PIH+100mM H2O2 0
Note: Cells were first treated with compounds (100 mM) for 18 h (except
PIH that was added to the serum-free medium for the duration of H2O2
treatment, that is, 30 min) and then treated (or sham-treated) with H2O2 at
a final concentration of 100mM. Measurements were performed immedi-
ately after radiation treatment. Kd of CA-Fe for FEK4 was 12.7.The
concentrations of LIP are expressed as means7SD, n=3.
*Significantly different from sham-irradiated control, Po0.05.
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neither BIH nor BnSIH treatment afforded protection against
UVA-induced cell death; the percentage of live cells in FEK4
cells remained unchanged when compared to the corre-
sponding UVA-irradiated control cells (Figure 4c).
At a moderate UVA dose of 250 kJ/m2, caged compounds
2-NPE-SIH and 2-NPE-PIH showed protection against UVA-
induced necrotic cell death over the range of 50–250 mM, but
the most effective protection was observed from final
concentrations of 100mM onwards (e.g. Figure 5). At a high
dose of 500 kJ/m2, only 2-NPE-PIH sustained its protective
effect against UVA-induced necrotic cell death (Figure 5a–d).
DISCUSSION
Our previous studies clearly demonstrate that exposure of
human skin fibroblasts and keratinocytes to UVA component
of sunlight promotes the immediate release of potentially
harmful labile iron in the cells. Further investigations show
that the immediate labile iron release following UVA-
irradiation originates mostly from iron liberated from the
Ft-bound pool following proteolytic degradation by lyso-
somal proteases released from damaged lysosomal organelles
(Pourzand et al., 1999). Absence of this critical iron storage
protein during the first hours following irradiation further
exacerbates the consequences of such iron release within
human skin cells, as the highly reactive LIP cannot be
controlled. Indeed, the increase in LIP is sustained for at least
2 hour following irradiation and only returns to basal levels
after 4–6 hours (Table 2 this study and Pourzand et al., 1999;
Reelfs et al., 2004; Zhong et al., 2004). This timing coincides
with Ft biosynthesis (Pourzand et al., 1999). The prolonged
presence of excess labile iron acts to increase dramatically
the level of UVA-induced oxidative damage to lysosomal,
mitochondrial, and plasma membrane (see, Zhong et al.,
2004 and unpublished data, this laboratory). Whereas low
UVA doses up to 150 kJ/m2 appear to cause reversible labile-
iron-induced oxidative damage, higher doses of radiation
causes cells to undergo necrotic cell death, presumably as
a result of severe irreversible damage to its components
(see, Pourzand et al., 1999; Pourzand and Tyrrell, 1999 and
Figure 4 of this study).
The direct link between UVA-induced iron release and
cytotoxicity suggests pathways of protection through iron
chelation. Previous studies from this laboratory demonstrated
that DFO treatment can substantially protect both cultured
skin fibroblasts and keratinocytes against UVA-mediated
membrane damage and necrotic cell death by depleting the
potentially harmful labile iron present in the cells (Pourzand
et al., 1999; Reelfs et al., 2004; Zhong et al., 2004). While
tempting to propose that strong chelators such as DFO can be
used as sunscreens additives, several studies link prolonged
exposure to iron chelators with deleterious side effects on
cells, tissues, and organs owing to systemic iron depletion
(e.g. Porter and Huens, 1989; Simonart et al., 2002).
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Figure 4. Effect of iron chelators SIH, PIH, and its derivatives on the
percentage of necrosis following UVA-irradiation of fibroblasts. (a)
Percentage live cells for Control and PIH-, SIH-, and DFO-treated cells.
(b) The corresponding percentage of necrotic cells. (c) Percentage live cells
for Control and BIH-, BnSIH-, and DFO-treated cells. (d) The corresponding
percentage of necrotic cells. Cells were first treated (or not, for ‘‘Control’’) for
18 hours with 100mM of compounds PIH, SIH, BIH, BnSIH, and DFO. Next,
the percentage of necrotic cell death was scored by flow cytometry 4 hours
following irradiation of cells with UVA doses of 0, 100, 250, and 500 kJ/m2.
Values are means7SD (n¼4–8). *, w, zSignificantly different from the
corresponding irradiated control, Po0.05.
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Figure 5. Effect of caged compounds 2NPE-SIH and 2-NPE-PIH on
the percentage of necrosis following UVA-irradiation of fibroblasts.
(a) Percentage live cells for Control and PIH- and 2-NPE-PIH-treated cells.
(b) The corresponding percentage of necrotic cells. (c) Percentage live cells
for Control and SIH- and 2-NPE-SIH-treated cells. (d) The corresponding
percentage of necrotic cells. Cells were first treated (or not, that is, ‘‘Control’’)
for 18 hours with 100 mM of compounds PIH, SIH, 2-NPE-PIH, and 2-NPE-SIH.
Next, the percentage of necrotic cell death was scored by flow cytometry
4 hours following irradiation of cells with UVA doses of 0, 100, 250, and
500 kJ/m2. Values are means7SD (n¼4–8). *, w, zSignificantly different from
the corresponding irradiated control, Po0.05.
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Herein, we describe a new strategy based on caged-iron
chelators that only release the active compound on exposure
to physiologically relevant doses of UVA-irradiation. Ideally,
such caged compounds should have (i) high lipophilicity to
enter easily the cells; (ii) low toxicity; (iii) no iron-chelation
property under normal conditions and high affinity for iron
upon UVA-irradiation; (iv) no toxic photo-by-products
released upon uncaging; (v) and most important, have highly
protective effect against UVA-induced damage and cytotoxi-
city. The lipophilic strong chelators SIH and PIH were used to
develop prototype caged compounds using the well-studied
ortho-nitrobenzyl derivatives (Kaplan et al., 1978). Our data
indicate that both caged compounds are sufficiently lipo-
philic to enter cells and tissues, display low affinity for iron
and no cytotoxicity and are therefore dispersed within skin
cells, without eliciting harmful side effects such as prolonged
iron starvation. Exposure of cells treated with the prototype
compounds to UVA light yields highly potent iron chelators
SIH and PIH that efficiently decrease the resulting labile
iron immediately following radiation treatment. Most impor-
tantly, this effect coincides with a reciprocal decrease in the
percentage of necrotic cell death. Cells treated with either
caged compounds were significantly protected against
UVA-induced necrotic cell death at a moderate UVA dose
of 250 kJ/m2 (i.e. at natural exposure levels). At a UVA higher
dose of 500 kJ/m2, only 2-NPE-PIH-treated cells exhibit
protection against UVA-induced necrotic cell death. Further-
more, as it can be seen in Figure 5b, the decrease in the
necrotic cell population for both PIH- and 2-NPE-PIH-treated
cells were almost identical for all the UVA doses used,
indicating that UVA converts 2-NPE-PIH to PIH. Additionally,
the photo-by-products of 2-NPE-PIH appear to have low
toxicity to the cells during the study period. Clearly, neither
the long-term administration of nitroaromatics nor the fact
that 2-nitrosobenzoyl photolysis products may undergo
potentially cytotoxic reaction with amines support the long-
term utility of these prototype compounds. Exploration of
more benign caging groups is anticipated as an essential
future development for the project.
2-NPE-SIH is only partially protective even at low to
moderate doses of UVA when compared to SIH, and not
protective at the high dose of 500 kJ/m2. The reason for this is
not clear, but one possible explanation is that the intracellular
localization of 2-NPE-SIH and 2-NPE-PIH are different and
that decaging is therefore less efficient, or that the photo-
products are harmful to cells, or themselves incapable of iron
chelation. In a related unpublished study from this laboratory,
we observed that unlike 2-NPE-PIH, PIH, and SIH, the caged
compound 2-NPE-SIH shows significant toxicity to lysosomal
membranes following irradiation of FEK4 cells with a high
UVA dose of 500 kJ/m2.
2-NPE-PIH provides demonstration of a novel concept
for the protection of skin cells against prolonged exposure
to sunlight. Whether this compound can be considered as
a potential sunscreen component requires further in vivo
studies and optimization and exploration of other caging
groups and iron chelators. At present, there are no caged
probes for iron available and the molecules that we have
synthesized may provide a useful addition to the arsenal
of chemical sensors available for biological studies. While
photodynamic therapy is well known (Dolmans et al., 2003)
and the methods for delivering light to target areas well
developed, there are very relatively few examples of prodrugs
activated by photolysis. This present study may invigorate
efforts in this area, although modulation of targeting and the
wavelength of release are anticipated here.
In summary, we describe here a totally different way
of approaching the protection of cells from UV damage.
Although the techniques of chelation and caging used here
are familiar, their combination and application in a com-
pletely novel arena make the target compounds very
innovative.
MATERIALS AND METHODS
Chemistry: synthesis of 2-NPE-SIH and 2-NPE-PIH – general
All solvents and reagents were purchased from commercial sources
and used as received. 1H and 13C NMR (nuclear magnetic
resonance) were obtained on a Varian EX-400 NMR spectrometer
at 400 and 100 MHz, respectively. Mass spectra were recorded at
University of Bath Mass Spectrometry Service on a VG Analytical
Autospec Mass Spectrometer using fast atom bombardment (FAB)
with 3-nitrobenzyl alcohol as a matrix. Elemental analysis was
performed at the University of Bath Service. Melting points were
determined using a Reichtert-Jung Therm Galen Kofler block and are
uncorrected. Reverse-phase high performance liquid chromato-
graphy analysis was performed on Varian Dynamax model SD-200
using a reverse-phase column (Kingsorb C18, 5 mm, 150 4.60 mm,
Phenomenex, Macclesfield Cheshire, UK) using isocratic elution
with 50% CH3CN–50% water with UV detection set at 282 nm.
General procedure for phenol alkylation. A solution of the
phenol (2.5 mmol), 1-(1-bromo-ethyl)-2-nitro-benzene, and Cs2CO3
in dimethyl formamide was stirred at 601C for 12 hours, then
concentrated under vacuum. The resulting crude was dissolved into
ethyl acetate, washed with 2 M aqueous NaOH, then brine and the
organics dried over sodium sulfate, dried and concentrated.
2-[1-(2-Nitrophenyl)ethoxy]benzaldehyde. 1H-NMR (400 MHz,
CDCl3) d1.77 (3H, d, J 6.3 Hz, CH3), 6.16 (1H, q, J 6.3 Hz, CHCH3),
6.69 (1H, d, J 7.8 Hz, ArH), 6.98 (1H, t, J 7.8 Hz, ArH), 7.37 (1H, dt,
J 7.8, 1.7 Hz, ArH), 7.45 (1H, dt, J 7.9, 1.4 Hz, ArH), 7.62 (1H, dt,
J 7.9, 1.4 Hz, ArH), 7.77 (1H, dd, J 7.9, 1.4 Hz, ArH), 7.82 (1H, dd,
J 7.8, 1.7 Hz, ArH), 8.04 (1H, dd, J 7.9, 1.4 Hz, ArH), 10.64 (1H, s,
CHO); 1H-NMR (100 MHz, CDCl3) 23.5, 72.1, 113.6, 121.3, 124.9,
125.3, 127.4, 128.7, 128.8, 134.4, 136.0, 138.2, 159.5, 189.6; and
m/z (FABþ ) 272.0927 (MþH, for C15H14NO4 required 272.0923).
6-Methyl-7-[1-(2-nitrophenyl)ethoxy]-1,3-dihydrofuro[3,4-c]
pyridin-1-ol. Chromatography on silica gel using ethyl acetate:
hexane (7:3) as eluent and recrystallization from ethyl acetate:
hexane gave the product as a beige powder. Mp 163–1651C; two
diastereoisomers A:B 6:4; 1H-NMR (400 MHz, CDCl3) A: d1.73 (3H,
d, J 6.3, CH3CH), 2.60 (3H, s, CH3Py), 4.19 (1H, brs, OH), 4.90 (1H,
d, J 12.7 Hz, CHaHb), 5.19 (1H, d, J 12.7 Hz, CHaHb), 6.14 (1H, s,
CHOH), 6.35 (1H, q, J 6.3 Hz, CHCH3), 7.46 (1H, dt, J 8.0, 1.3 Hz,
ArH), 7.67 (1H, dt, J 8.0, 1.3 Hz, ArH), 7.84 (1H, dd, J 8.0, 1.3 Hz,
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ArH), 8.01 (1H, dd, J 8.0, 1.3 Hz, ArH), 8.05 (1H, s, PyH); B: 1.72
(3H, d, J 6.3 Hz, CH3CH), 2.58 (3H, s, CH3Py), 4.19 (1H, brs, OH),
4.99 (1H, d, J 12.7 Hz, CHaHb), 5.20 (1H, d, J 12.7 Hz, CHaHb), 6.22
(1H, q, J 6.3 Hz, CHCH3), 6.55 (1H, s, CHOH), 7.46 (1H, dt, J 8.0,
1.3 Hz, ArH), 7.72 (1H, dt, J 8.0, 1.3 Hz, ArH), 7.96 (1H, dd, J 8.0,
1.3 Hz, ArH), 8.04 (1H, dd, J 8.0, 1.3 Hz, ArH), 8.07 (1H, s, PyH);
13C NMR (100 MHz, CDCl3) (two diastereoisomers): d19.8, 19.9,
23.6, 23.9, 69.6, 69.7, 74.8, 75.6, 99.6, 99.7, 124.5, 124.9, 127.4,
127.9, 128.5, 128.6, 133.9, 134.1, 135.0, 135.1, 135.3, 135.4,
135.7, 135.8, 139.1, 147.0, 147.1, 147.2, 150.2, 150.4; HRMS
(FABþ ) calcd. for C16H17N2O5 317.1137 (MþH); found
317.11404 (MþH); anal. calcd. C16H16N2O5: C, 60.75, H, 5.10,
N, 8.86; found: C, 60.40, H, 5.08, N, 8.93.
General procedure for hydrazide formation. A solution of
aldehyde (6, or 7, 1 mmol,) and isonicotinic acid hydrazide (1 mmol)
in ethanol:water (9:1, 10 ml) was heated at reflux for 24 hours.
Isonicotinic acid [1-{5-hydroxymethyl-2-methyl-[1-(2-nitro-
phenyl)-ethoxy]-pyridin-4-yl}-meth-(E)-ylidene]-hydrazide 2.
Obtained as a white precipitate from the cooled reaction mixture,
82%. mp 227–2291C; 1H-NMR (400 MHz, (CD3)2SO, Me4Si) 1.73
(3H, d, J 6.2 Hz, CH3), 6.09 (1H, q, J 6.2 Hz, CHO), 6.85 (1H, d,
J 7.9 Hz, ArH), 7.01 (1H, t, 7.9 Hz, ArH), 7.30, (1H, dt, J 7.9, 1.7 Hz,
ArH), 7.60 (1H, dt, J 7.2, 1.7 Hz, ArH), 7.67–7.82 (2H, m, ArH), 7.88
(2H, d, J 6.1 Hz, PyH), 7.91 (1H, dd, J 7.9, 1.7 Hz, ArH), 8.08 (1H,
dd, J 7.2, 1.7 Hz, ArH), 8.82 (2H, d, J 6.1 Hz, PyH), 8.37 (1H, s,
CHN), 12.17 (1H, s, NH); 13C NMR (100 MHz, (CD3)2SO, Me4Si)
23.3, 71.7, 114.2, 121.9, 122.1, 123.4, 125.2, 126.5, 127.7, 129.7,
132.2, 134.8, 137.5, 141.1, 144.7, 148.0, 150.8, 155.8, 162.0;
HRMS (FAB) calcd. for C21H19N4O4: 391.14063 (MþH); found
391.14207 (MþH); anal. calcd. C21H18N4O4: C, 64.61, H, 4.65, N,
14.35; found: C, 64.60, H, 4.68, N, 14.30.
Isonicotinic acid [1-{5-hydroxymethyl-2-methyl-3-[1-(2-nitro-
phenyl)-ethoxy]-pyridin-4-yl}-meth-(E)-ylidene]-hydrazide 1.
Reaction performed in presence of Dowexs 50WX4-50 acidic resin,
filtered, and concentrated reaction mixture was purified by column
chromatography on silica gel eluting from 0.5:99.0 methanol and
dichloromethane to 5.0:95.0, then recrystallized from ethyl acetate/
ethanol to afford the title compound as a white powder, 65%. Mp
191–1931C; 1H-NMR (400 MHz, (CD3)2SO) 1.63 (3H, d, J 6.2 Hz,
CH3CHO), 2.36 (3H, s, CH3Py), 4.66 (2H, d, J 6.3 Hz, CH2OH), 5.28
(1H, t, J 6.3 Hz, OH), 5.50 (1H, q, J 6.2 Hz, CHO), 7.61 (1H, dt,
J 7.9 Hz, 1.2, ArH), 7.83 (2H, d, J 5.9 Hz, PyH), 7.87 (1H, dt, J 7.9,
1.2 Hz, ArH), 7.96 (1H, dd, J 7.9, 1.2 Hz, ArH), 8.11 (1H, dd, J 7.9,
1.2 Hz, ArH), 8.43 (1H, s, CHN), 8.66 (1H, s, PyH), 8.84 (2H, d,
J 5.9 Hz, PyH), 12.38 (1H, s, NH); 13C NMR (100 MHz, (CD3)2SO)
20.1, 22.4, 60.5, 77.4, 122.0, 124.6, 129.2, 129.9, 132.7, 134.27,
134.33, 136.2, 140.4, 144.3, 144.7, 148.0, 150.3, 151.0, 152.0,
162.6; HRMS (FAB) calcd. for C22H22N5O5: 436.16209 (MþH);
found 436.16073 (MþH); Anal. calcd. C22H21N5O5: C 60.68, H
4.86, N 16.08; found: C 60.60, H 4.86, N 16.00.
Cell biology
The medical ethical committee of the University of Bath approved all
described studies. The study was conducted according to The
Declaration of Helsinki Principles.
Chemicals. All the Cell biology reagents were from Sigma
Chemical (St-Louis, MO), except Annexin V (Roche, Lewes, UK),
DFO (Desferal from Novartis, Basel, Switzerland), CA-AM (calcein-
acetoxymethyl ester; Molecular Probes, Eugene, OR), and Apoglow
kit reagents (Lumitech, Nottingham, UK). Cell culture materials were
from Life Technologies (Paisley, Scotland), except fetal calf serum
(PAA Laboratories, Teddington, UK) and phosphate-buffered saline
(Oxoid Basingstoke, UK). Stock solutions were prepared in
phosphate-buffered saline, except DFO and PI in water, PIH (Baker
et al., 1992) in 1 N HCl, and SIH (Baker et al., 1992), 2NPE-SIH, and
2-NPE-PIH in DMSO. Final concentration of DMSO in the medium
did not exceed 0.2%. The water used to prepare solutions was from a
MilliQ purification system (Millipore, Bedford, MA) in order to
minimize the presence of trace elements such as transition metals.
Cell culture. The human fibroblast cell line FEK4 (kindly provided
by R. M. Tyrrell, Bath University, UK) was derived from newborn
foreskin explants (Zhong et al., 2004). Fibroblast (3.5 105; passages
12–14) monolayers were grown in 10 cm dishes for 3–4 days in order
to reach 80% confluency on the day of the experiment as described
previously (Pourzand et al., 1999).
Irradiation. Irradiations were performed in phosphate-buffered
saline at approximately 251C using a broad-spectrum Sellas 4 kW
UVA lamp (Sellas, Germany), as described previously (Pourzand
et al., 1999). UVA doses were measured using an IL1700 radiometer
(International Light, Newbury, MA). Control cells were treated in the
same manner, except that they were not irradiated (i.e. sham
irradiation).
CA loading and intracellular LIP estimation. The method used
to estimate the level of intracellular CA-bound iron (CA-Fe) was
modified from Epsztejn et al. (1997) as described previously
(Pourzand et al., 1999; see, Kakhlon and Cabantchik, 2002). To
determine the intracellular level of LIP, which is operationally
defined as the sum of the intracellular level of CA-bound iron (i.e.
[CA-Fe]) and free iron (i.e. [Fe] unbound to CA), the cell-dependent
dissociation constant (Kd) for CA-Fe was obtained as described
previously (Zhong et al., 2004). From the Kd value, the absolute
intracellular level of free iron (i.e. [Fe] unbound to CA) was then
calculated and the results expressed as micromolar concentration
of LIP (i.e. [CA-Fe]þ [Fe]). When cells were treated with SIH, the
dequenching of the CA-Fe was performed with PIH and confirmed
with DFO.
Intracellular LIP estimation by IRP/ IRE RNA bandshift assay.
To evaluate the modulation of the basal LIP levels in cells treated
with various compounds, we employed the IRP/IRE (iron regulatory
protein/iron-responsive element) RNA- bandshift assay. In this
method, the level of iron is monitored by the formation of complexes
between IRP and the IRE of ferritin (Ft) mRNA as described
previously (Pourzand et al., 1999; see, Kakhlon and Cabantchik,
2002). Briefly, the cytoplasmic extracts were first prepared at the
indicated time following treatment with the compounds according to
Mu¨llner et al. (1992) and then probed with gel-purified 32P-labeled
wild-type (i.e. recognizes both IRP-1 and IRP-2) or IRP-1-specific
RNAs (kindly provided by L. Kuhn, Swiss Institute For Experimental
Cancer Research, Switzerland; see, Henderson et al., 1996) in the
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presence of 5 mg/ml heparin. RNA–protein complexes were resolved
on a 6% non-denaturing gel and processed for autoradiography.
Quantification of the IRP/IRE signals was carried out with a Phos-
phorImager (Molecular Dynamics, Sunnyvale, CA) using IMAGE-
QUANT software 3.3 (National Institutes of Health, Bethesda, MD).
Flow cytometry. The percentage of apoptotic and necrotic cells
were scored after dual staining of cells with PI and Annexin V-FITC
staining by flow cytometry using the FACS vantage (Becton
Dickinson) as described previously (Zhong et al., 2004). Double-
stained cells and Annexin V-negative/PI-positive cells were consi-
dered ‘‘necrotic’’, whereas Annexin V-positive/ PI-negative cells
were ‘‘apoptotic’’. Annexin V-negative/PI-negative were the ‘‘live’’
cells.
Statistical methods. Results are expressed as the mean7SD.
Significant differences (Po0.05) were determined by either paired or
unpaired t-test after one-way analysis of variance.
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